NCT03456687 is a Phase 1 clinical trial of Exenatide in Parkinson's Disease, sponsored by University of Florida.

Who is sponsoring NCT03456687?

NCT03456687 is sponsored by University of Florida.

What drugs are being tested in NCT03456687?

Interventions in NCT03456687: Exenatide.

What condition does NCT03456687 study?

NCT03456687 studies Parkinson's Disease.

Is NCT03456687 still recruiting?

NCT03456687 is currently completed. Last updated 16 September 2022.

Last reviewed 2022-09-16 · How we verify

NCT03456687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Exenatide on Motor Function and the Brain

Completed Phase 1 Last updated 16 September 2022

What this trial tests

Phase 1 trial testing Exenatide in Parkinson's Disease in 5 participants. Completed in 25 August 2021.

Timeline

5 June 2018

Primary endpoint
16 October 2020

25 August 2021

Quick facts

Lead sponsor	University of Florida
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	5 June 2018
Primary completion	16 October 2020
Estimated completion	25 August 2021
Sites	1 location across United States

Drugs / interventions tested

Exenatide (EXENATIDE) — full drug profile →

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

University of Florida

Who can join

Adults 40 to 77, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to investigate how the brain and motor behavior changes Parkinson's Disease (PD) over time in response to Exenatide. In previous clinical trials, PD patients have experienced symptomatic improvement on Exenatide and literature suggests it may help slow the progression of Parkinson's. Both will be evaluated in this study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery.
Bordon KCF, Cologna CT, Fornari-Baldo EC, Pinheiro-Júnior EL, et al · · 2020 · cited 193× · PMID 32848750 · DOI 10.3389/fphar.2020.01132
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
Kopp KO, Glotfelty EJ, Li Y, Greig NH. · · 2022 · cited 185× · PMID 36372278 · DOI 10.1016/j.phrs.2022.106550
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.
Diz-Chaves Y, Mastoor Z, Spuch C, González-Matías LC, et al · · 2022 · cited 89× · PMID 36076972 · DOI 10.3390/ijms23179583
Novel targeted therapies for Parkinson's disease.
Ntetsika T, Papathoma PE, Markaki I. · · 2021 · cited 78× · PMID 33632120 · DOI 10.1186/s10020-021-00279-2
GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease.
Kalinderi K, Papaliagkas V, Fidani L. · · 2024 · cited 63× · PMID 38612620 · DOI 10.3390/ijms25073812
Parkinson's disease and diabetes mellitus: common mechanisms and treatment repurposing.
Labandeira CM, Fraga-Bau A, Arias Ron D, Alvarez-Rodriguez E, et al · · 2022 · cited 47× · PMID 35017411 · DOI 10.4103/1673-5374.332122
Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies.
Chmielarz P, Saarma M. · · 2020 · cited 40× · PMID 32700249 · DOI 10.1007/s43440-020-00120-3
Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease.
Hong CT, Chen JH, Hu CJ. · · 2024 · cited 35× · PMID 39501255 · DOI 10.1186/s12929-024-01090-x

Verify or expand the search:

Other trials of Exenatide

Trials testing the same drug.

NCT05663515 — A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated E · recruiting
NCT06252623 — Exenatide For Reducing the Reinforcing Effects of Cocaine · Phase 1 · withdrawn
NCT02586831 — Diabetes Islet Preservation Immune Treatment · Phase 1, PHASE2 · withdrawn
NCT05482789 — Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes · Phase 4 · recruiting
NCT04909333 — Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia · NA · completed

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03456687 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 16 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03456687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing